Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Between being a cast member on The Real Housewives of New Jersey, starring in the latest season of the hit competition show ...

But while basic research continues slowly, a flood of Ozempic competitors are rushing to market. Some of them may work even better than Ozempic at causing weight loss. Mounjaro, from a company ...

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

KEY TAKEAWAYSNovo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

In 2020, Ozempic was granted additional approval to ... with type 2 diabetes with known heart disease. Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's (LLY) tirzepatide ...

Competitor Novo Nordisk had initially planned ... In 2022, over 65% of all drug prescriptions in the US were for Ozempic alone. Patanjali’s big claim, bigger trouble: Arrest warrant issued ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...